European Heart Journal Advance Access originally published online on March 31, 2005
European Heart Journal 2005 26(12):1169-1179; doi:10.1093/eurheartj/ehi238
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization
1Department of Cardiology, Erasmus MC, Thoraxcenter, Rotterdam, The Netherlands
2Division of Cardiology, Lille University Heart Institute, Lille, France
3Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
4Cardiology Service, Hospital Central de Asturias, Asturias, Spain
5Division of Cardiology, Federico II University, Naples, Italy
6Department of Cardiology, Robert-Bosch-Krankenhaus, Stuttgart, Germany
7Thoracic and Cardiovascular Surgery, University Hospital, Uppsala, Sweden
8University Hospital Vinohrady, Prague, Czech Republic
9Cardiovascular Centre, OLV Hospital, 164 Moorselbaan, B 9300 Aalst, Belgium
Received 6 December 2004; revised 10 February 2005; accepted 23 February 2005; online publish-ahead-of-print 31 March 2005.
* Corresponding author. Tel: +32 53724439; fax: +32 53724185.E-mail address: william.wijns{at}olvz-aalst.be
See page 1147 for the editorial comment on this article (doi:10.1093/eurheartj/ehi247)
Aims The purpose of the Euro Heart Survey Programme of the European Society of Cardiology is to evaluate to which extent clinical practice endorses existing guidelines as well as to identify differences in population profiles, patient management, and outcome across Europe. The current survey focuses on the invasive diagnosis and treatment of patients with established coronary artery disease (CAD).
Methods and results Between November 2001 and March 2002, 7769 consecutive patients undergoing invasive evaluation at 130 hospitals (31 countries) were screened for the presence of one or more coronary stenosis >50% in diameter. Patient demographics and comorbidity, clinical presentation, invasive parameters, treatment options, and procedural techniques were prospectively entered in an electronic database (550 variables+29 per diseased coronary segment). Major adverse cardiac events (MACE) were evaluated at 30 days and 1 year. Out of 5619 patients with angiographically proven coronary stenosis (72% of screened population), 53% presented with stable angina while ST elevation myocardial infarction (STEMI) was the indication for coronary angiography in 16% and non-ST segment elevation myocardial infarction or unstable angina in 30%. Only medical therapy was continued in 21%, whereas mechanical revascularization was performed in the remainder [percutaneous coronary intervention (PCI) in 58% and coronary artery bypass grafting (CABG) in 21%]. Patients referred for PCI were younger, were more active, had a lower risk profile, and had less comorbid conditions. CABG was performed mostly in patients with left main lesions (21%), two- (25%), or three-vessel disease (67%) with 4.1 diseased segments, on average. Single-vessel PCI was performed in 82% of patients with either single- (45%), two- (33%), or three-vessel disease (21%). Stents were used in 75% of attempted lesions, with a large variation between sites. Direct PCI for STEMI was performed in 410 cases, representing 7% of the entire workload in the participating catheterization laboratories. Time delay was within 90 min in 76% of direct PCI cases. In keeping with the recommendations of practice guidelines, the survey identified under-use of adjunctive medication (GP IIb/IIIa receptor blockers, statins, and angiotensin-converting enzyme-inhibitors). Mortality rates at 30 days and 1 year were low in all subgroups. MACE primarily consisted of repeat PCI (12%).
Conclusion The current Euro Heart Survey on coronary revascularization was performed in the era of bare metal stenting and provides a global European picture of the invasive approach to patients with CAD. These data will serve as a benchmark for the future evaluation of the impact of drug-eluting stents on the practice of interventional cardiology and bypass surgery.
Key Words: Coronary artery disease Coronary angiography CABG PCI Practice survey
![]()
CiteULike
Connotea
Del.icio.us What's this?
Related articles in EHJ:
- Optimizing management of patients with coronary artery disease: how do we get there?
- Debabrata Mukherjee
EHJ 2005 26: 1147-1149.[Extract] [FREE Full Text]
This article has been cited by other articles:
![]() |
K. J.E. Sattler, J. Herrmann, S. Yun, N. Lehmann, Z. Wang, G. Heusch, S. Sack, R. Erbel, and B. Levkau High high-density lipoprotein-cholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves long-term outcome in patients undergoing elective percutaneous coronary intervention Eur. Heart J., August 1, 2009; 30(15): 1894 - 1902. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Yap, B. P. Yan, E. Akowuah, D. T. Dinh, J. A. Smith, G. C. Shardey, J. Tatoulis, P. D. Skillington, A. Newcomb, M. Mohajeri, et al. Does Prior Percutaneous Coronary Intervention Adversely Affect Early and Mid-Term Survival After Coronary Artery Surgery? J. Am. Coll. Cardiol. Intv., August 1, 2009; 2(8): 758 - 764. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Onuma, N. Kukreja, J. Daemen, H. M. Garcia-Garcia, N. Gonzalo, J. M. Cheng, P. H. van Twisk, R. van Domburg, P. W. Serruys, and on behalf of the Interventional Cardiologists of T Impact of Sex on 3-Year Outcome After Percutaneous Coronary Intervention Using Bare-Metal and Drug-Eluting Stents in Previously Untreated Coronary Artery Disease: Insights From the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries J. Am. Coll. Cardiol. Intv., July 1, 2009; 2(7): 603 - 610. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Crea, P. G. Camici, R. De Caterina, and G. A. Lanza CHAPTER 17 Chronic Ischaemic Heart Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Sanz-Ruiz and F. Fernandez-Aviles European perspective on the use of antiplatelet agents in atherothrombotic disease Eur. Heart J. Suppl., November 1, 2008; 10(suppl_I): I14 - I18. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ebbing, O. Bleie, P. M. Ueland, J. E. Nordrehaug, D. W. Nilsen, S. E. Vollset, H. Refsum, E. K. Ringdal Pedersen, and O. Nygard Mortality and Cardiovascular Events in Patients Treated With Homocysteine-Lowering B Vitamins After Coronary Angiography: A Randomized Controlled Trial JAMA, August 20, 2008; 300(7): 795 - 804. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Corbett Ethical issues, justification, referral criteria for budget limited and high-dose procedures Radiat Prot Dosimetry, June 1, 2008; 130(2): 125 - 132. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M Sibai, R. A Tohme, G. A Saade, G. Ghanem, S. Alam, and for the Lebanese Interventional Coronary Registry The appropriateness of use of coronary angiography in Lebanon: implications for health policy Health Policy Plan., May 1, 2008; 23(3): 210 - 217. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Brown, T. M. Sundt III, and B. J. Gersh Indications for Revascularization Card. Surg. Adult, January 1, 2008; 3(2008): 551 - 572. [Full Text] |
||||
![]() |
D. G. Katritsis, J. P.A. Ioannidis, T. P. Wharton Jr., V. A. Umans, H. O. Peels, A. P. Shah, D. M. Shavelle, W. J. French, S. De Servi, H. Kiat, et al. PCI for Stable Coronary Disease N. Engl. J. Med., July 26, 2007; 357(4): 414 - 418. [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF] |
||||
![]() |
E. Camenzind, P. G. Steg, and W. Wijns A Cause for Concern Circulation, March 20, 2007; 115(11): 1440 - 1455. [Full Text] [PDF] |
||||
![]() |
M. J Lenzen, W. J M Scholte op Reimer, S. S Pedersen, E. Boersma, W. Maier, P. Widimsky, M. L Simoons, N. F Mercado, W. Wijns, and on behalf of the investigators of the Euro Heart S The additional value of patient-reported health status in predicting 1-year mortality after invasive coronary procedures: a report from the Euro Heart Survey on Coronary Revascularisation Heart, March 1, 2007; 93(3): 339 - 344. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tobis, B. Azarbal, and L. Slavin Assessment of Intermediate Severity Coronary Lesions in the Catheterization Laboratory J. Am. Coll. Cardiol., February 27, 2007; 49(8): 839 - 848. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Breeman, M. Hordijk-Trion, M. Lenzen, S. Hoeks, J. P. Ottervanger, M. E. Bertrand, U. Sechtem, R. Zaliunas, V. Legrand, M.-J. de Boer, et al. Treatment decisions in stable coronary artery disease: insights from the Euro Heart Survey on Coronary Revascularization. J. Thorac. Cardiovasc. Surg., November 1, 2006; 132(5): 1001 - 1009. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Breeman, M. E. Bertrand, J. P. Ottervanger, S. Hoeks, M. Lenzen, U. Sechtem, V. Legrand, M.-J. de Boer, W. Wijns, E. Boersma, et al. Diabetes does not influence treatment decisions regarding revascularization in patients with stable coronary artery disease. Diabetes Care, September 1, 2006; 29(9): 2003 - 2011. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Camm How does pure heart rate lowering impact on cardiac tolerability? Eur. Heart J. Suppl., September 1, 2006; 8(suppl_D): D9 - D15. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hordijk-Trion, M. Lenzen, W. Wijns, P. de Jaegere, M. L. Simoons, W. J.M. Scholte op Reimer, M. E. Bertrand, N. Mercado, E. Boersma, and on behalf of the EHS-CR Investigators Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization Eur. Heart J., March 2, 2006; 27(6): 671 - 678. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Tavazzi The need to identify new targets for therapeutic intervention in angina Eur. Heart J. Suppl., February 1, 2006; 8(suppl_A): A3 - A5. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Beyar, L. Gruberg, D. Deleanu, A. Roguin, Y. Almagor, S. Cohen, G. Kumar, and T. Wenderow Remote-Control Percutaneous Coronary Interventions: Concept, Validation, and First-in-Humans Pilot Clinical Trial J. Am. Coll. Cardiol., January 17, 2006; 47(2): 296 - 300. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mukherjee Optimizing management of patients with coronary artery disease: how do we get there? Eur. Heart J., June 2, 2005; 26(12): 1147 - 1149. [Full Text] [PDF] |
||||













